SCBIO believes growing the life sciences sector will significantly transform the state’s economy. see more
Compliments of the Community Journal...
It was all smiles on Sept. 30 as BMW marked the 25th anniversary of the first vehicle to roll off its Spartanburg assembly line, a singular moment that dramatically transformed the economic face of South Carolina.
A quarter-century after opening, the German manufacturer’s North American facility employs more than 11,000 workers who build 1,500 vehicles daily, a pace requiring the services of more than 40 main suppliers across the state.
The average wage among all S.C. jobs supported by the automotive industry stood at $64,120 in 2017 compared to $40,293 across all employment categories, say findings commissioned by the South Carolina Biotechnology Industry Organization (SCBIO).
Now three years old, SCBIO is spearheading an aggressive initiative to make South Carolina the preferred location for new or expanding companies in another highly promising industry: life sciences. Read the entire story by clicking here.
SCBIO, business community shaping curriculato grow life sciences careers see more
Compliments of GSA Business and SCBIZ
South Carolina’s life science sector creates twice as many jobs as the average of all other sectors in the state economy, according to a recent study, but whether it can fill those positions is another matter — especially in the manufacturing and logistics side of the house.
The life science fields are struggling to fill positions in the fast-growing sector. (Photo/Provided)
“It has historically been the majority of the time that you find a qualified person, they already have a job in M&L (manufacturing and logistics), so it has really been tough to fill the need,” said Josh Turner, a sales executive for Modjoul, a health-focused data analytics company that serves the manufacturing sector. Turner is also a former staffing professional.
He added that staffing companies pre-pandemic were filling positions with available people even if they weren’t trained or had any experience in the field.
“All I’ve heard since the pandemic is [that] it has been hard to even find available people, much less available and qualified people,” he said.
This gap is even more prominent in a life science field that sometimes requires more than the standard specialization or training. And to add insult to injury, few in-school training programs target this unique brand of manufacturing and logistics, said SCBIO interim CEO Erin Ford.
“The life sciences encompasses so many aspects from medical devices to pharmaceutical research and development to logistics in getting the drugs or pharmaceuticals or medical devices to where they need to be,” she said. “There's just so many aspects to the life sciences. And we really, as a state, have not focused on having any specific curriculum or programs that are specialized in this area.”
She argued that while the traditional medical careers such as nursing fall under the Life Science umbrella, industrial aspects of the sector often get overlooked in the classroom.
“It’s just not even a part of the discussion as to what career you want to have,” Ford said.
Arthrex and Tri-County Tech have had an existing apprenticeship partnership since 2020. (Photo/Provided)
Since the economic development organization formed its Workforce Development Taskforce a few years ago, its more than 300 members have aimed to do something about that.
She hopes that 2021 (or early 2022) will be the year she can see their work come to fruition through a curriculum pilot geared toward two-year students in South Carolina’s technical college network.
Students upon learning about the field may often feel intimidated by the math or science components attached to a traditional science, technology, engineering and math field, she said, but really it’s the requirements of working in a clean room in the medical device field that can prove to be the most challenging.
And that is the gap Ford hopes the program will fill.
So far, Tri-County Technical College, Trident Technical College, Greenville Technical College and Midlands Technical College have signed on to the pilot, she said, which covers a track for pharmaceutical or biotech professionals and those seeking a career in the medical device field.
“We don't want to reinvent the wheel,” Ford said. “That's why we're working with a lot of the partners to add in more substance for life sciences. So if we see that there is more for us to do, we will definitely take that on.”
Life science companies in each region have already offered up some input to their needs and will continue to do so once the program launches: Trident Technical College has its ear to the ground for workforce demands of Alcami, Charles River Labs and Vikor Scientific while Tri-County Technical College is partnering with Arthrex, Abbott Laboratories and Poly-Med. Midlands Tech has an open channel to the demands of medical device companies Rhythmlink and Nephron Pharmaceuticals.
“You’ve seen the map, right? Of the 700 life science companies? The kids just don’t know,” she told GSA Business Report, adding that it’s the job of SCBIO and its partners to share the story of the state’s abundance of life science firms and manufacturers.
Medical device manufacturer Poly-med CEO Dave Shalaby said his company usually hires Clemson University graduates and has a strong in-house program, but now that the hiring climate has become so competitive in the Upstate, he has started to advise Tri-County Tech on courses that would expose students to the industry’s ISO 1345 standards and documentation.
“And really surprisingly, it's not really geared toward the sciences as much as it's geared toward control, like how to control processes and design, and also there's a lot of statistics involved with showing proof that you're adhering to specific specifications that you've set,” Shalaby said. “So basically the course outline that we set up with Tri-County is to give them exposure to those sorts of things.”
Tri-County instructors will teach company and industry requirements, he said, and help create a workforce pipeline to Poly-med, Arthrex and Abbott.
“Tri-County is developing that curriculum now,” he said. “They’ve got sort of a draft in place, and it’s got to come back out for everybody to take a look at it and see if it makes sense to create the course.”
The course would help prime students for employment at partnering industries like Poly-med, and Ford foresees a potential apprenticeship route on a case-by-case basis. SCBIO has been in conversation with Apprenticeship Carolina’s Carla Whitlock on those possibilities.
In the meantime, Ford encouraged other industry voices interested in contributing to the program through input or partnership to get in touch and jump on board.
“Reach out to us,” she said. “Reach out to me and SCBIO, because the more industry that we can have involved in these programs, the more successful it will be.”
Multi-year plan designed to help drive growth of industry across Palmetto State see more
SCBIO CEO Erin Ford only has to look at recent history to understand the opportunity in front of South Carolina life sciences.
Life sciences has a $12+ billion economic impact in the Palmetto State, with more than 700 firms involved and over 43,000 professionals employed in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental, and agricultural biotechnology products.
It represents a significant economic development focus for the state, with strong life science recruiting initiatives led by the South Carolina Department of Commerce and regional economic development teams – so much so that Governor McMaster recently issued an Executive Order to emphasize the industry in domestic and international recruiting efforts.
Now armed with the industry’s third multi-year Strategic Plan to build, advance, innovate and grow the industry, Ms. Ford sees an opportunity to “take South Carolina life sciences to an entirely new level” over the next handful of years, she said as SCBIO published the 2021-2022 Life Sciences Strategic Plan recently.
Ms. Ford is no stranger to leading the industry. Since taking over as interim CEO for the departed Sam Konduros just weeks ago, she has expanded emphasis on investor relations and existing industry support strategies, the spearheading of integrated marketing initiatives, implementation of the new SCBIO innovation platform, and a strong emphasis on economic development initiatives – from an industrywide presence at this week’s PGA Tournament at Kiawah to next month’s BIO Global conference and the Fall MEDICA event in Germany.
Guided by the new Strategic Plan, which spans 24 months and continues the vision of the last two editions, SCBIO and SC life sciences are clearly focused on doing “the right things to continue to build, advance, innovate and grow” the multifaceted industry.
SC Life Sciences 2021-2022 Strategic Plan is shaped by input from SCBIO’s Board of Directors and dozens of contributors from industry, higher education, economic development, government and supporting organizations and authored by the SCBIO team. The 70-page document includes detailed sections on the COVID Effect on the industry, 2020 Highlights, documentation of the breadth and depth of the Industry Segments in the state, Priority Initiatives, and specific Objectives, Plans and Budgets to advance life sciences.
A shorter summarized version is available to media and business leaders interested in learning more about the fastest-growing industry in South Carolina, as documented recently by Dr. Joseph Von Nessen, economist with the Moore School of Business at the University of South Carolina. To request a copy, interested persons should email firstname.lastname@example.org.
South Carolina life sciences has seen a near-doubling of firms and 40% increase in life sciences’ direct employment since 2017 alone, which combine to make it the fastest growing industry sector in the state, according to recent data provided by Dr. Von Nessen, state research economist and a noted economic development expert. It also has companies in 42 of 46 counties – a far greater penetration than most major industries possess.
The 2021-2022 plan seeks to continue the growth strategies of the industry evident over the last four years during which Ms. Ford served as EVP/COO prior to assuming the interim role of CEO. During those four years, SCBIO has more than doubled membership and quadrupled revenues, implemented a strong economic development focus, and launched a new innovation platform. It expanded its role as the voice of the life sciences industry, implemented a surging workforce development initiative and created ongoing programs to encourage participation by women in life sciences, to support diversity-equity-inclusion initiatives and to encourage student participation in the industry. The organization also successfully led industry and organizational pivots during the COVID pandemic.
“Prior SC life sciences plans have performed admirably in helping South Carolina raise its profile as an emerging leader in the life sciences,” said Ms. Ford. “Our innovative companies and exceptional workforce are drivers in strengthening this industry, and we know that the life sciences will continue to play a critically important role in our state’s economic success. We intend to build on our Board’s and team’s vision to continue this momentum and to build, advance and grow life sciences in our state.”
Newly elected President's plans have major bearing on the medtech industry see more
While former Vice President Joe Biden and the team he builds won't take office for another two months, the campaign’s plans for COVID-19, healthcare and other policy areas offer clues to how changing tides in Washington may impact the medtech industry.
In approaching the top task at hand — getting the pandemic under control — the Democrat's plan includes proposals with implications for the industry, from how diagnostic testing is covered to access to telemedicine services.
In some ways, the act of swapping out administrations, regardless of who's in power, means device makers can anticipate shifts at key government agencies like the FDA.
ZEUS Names New President and CEO see more
Frank P. Tourville, Sr., Founder and Chairman of the Board of Zeus Industrial Products, Inc. announced on Wednesday, July 1, 2020 that Steve Peterson, President of Zeus, assumed the role of Chief Executive Officer. This organizational change comes with the recent retirement of former CEO, John Winarchick, who dedicated over 30 years of service to the company.
Peterson, who joined Zeus in 2017, previously held the position of Senior Vice President of Global Sales and Marketing. Before joining Zeus, Peterson held global leadership positions with TE Connectivity, Samsung Electronics, and General Electric. During that time, he assumed roles of increasing responsibility in sales, marketing, product management, supply chain management, and executive management.
As President and CEO of Zeus, Peterson will continue to play an instrumental role in leading the company forward by focusing on developing powerful growth strategies and providing ongoing value to customers, team members, and the surrounding communities. His invaluable contributions have already helped to shape the company Zeus is today.
“Steve Peterson has shown the true measure of a leader in unprecedented times of difficulty. His charisma, resilience, dedication, and vast industry knowledge are huge assets to Zeus,” said Frank P. Tourville, Sr., Founder and Chairman of the Board, Zeus Industrial Products, Inc.
SCRA added three advisory groups for biomedical sciences, cybersecurity and industry see more
Summerville, S.C.—South Carolina Research Authority (SCRA) announces the formation of three Business and Science Advisory Boards (BSABs). The purpose of the BSABs is to advise SCRA’s Board of Trustees when requested by it. The boards include representatives from South Carolina research universities, the venture capital/angel investment community, South Carolina Department of Commerce, and industry leaders in the following areas:
Each board provides key business and technical expertise, acts as an independent/ unbiased sounding board for input on SCRA’s program implementation and performance and provides guidance to SCRA regarding funding opportunities. One upcoming funding opportunity on which the BSABs will advise is the SCRA-Academia Collaboration Team (SACT) Collaborative Research Grants. These grants will be available for multi-institutional, collaborative research teams that seek to advance commercially relevant research and address key industry challenges to foster technology-enabled growth of the state’s innovation economy. The solicitation will be released in June.
“SCRA serves as a bridge between industry and academia. It is imperative that the applied research SCRA funds benefits not only its academic stakeholders, but also South Carolina’s industrial base. The development of the BSABs ensures that the new SACT program achieves those objectives for both stakeholder groups,” said Christine Dixon Thiesing, SCRA Director of Academic Innovations.
The SCRA fuels South Carolina’s innovation economy by accelerating technology-enabled growth in academia, entrepreneurship and industry. SCRA works with public and private sectors, including industry, to identify market trends and validate the commercial relevance of academic research that SCRA funds. SCRA’s programs and operations had an almost $700 million impact on the state’s economy during the last fiscal year.
Chartered in 1983 by the State of South Carolina as a public, nonprofit corporation, SCRA fuels South Carolina’s Innovation Economy by accelerating technology-enabled growth in research, academia, entrepreneurship and industry.
Clemson, Prisma Health to collaborate on developing new medical treatments see more
Researchers at Clemson University and Prisma Health have received funding to collaborate on the development of new medical treatment and diagnostic technologies.
Three Clemson-Prisma Health collaborations received investments from the recently created Innovation Maturation Fund, a joint effort between the Health Sciences Center (HSC) at Prisma Health and the Clemson University Division of Research. The program provides health care-focused grants designed to advance the development and commercialization of innovative medical initiatives and translational science, to improve the health care industry and to promote economic growth in the region.
The projects supported by this fund include a system to monitor triggers affecting respiratory health, injectable tissue regeneration technology and a monitoring device for patients with chronic kidney disease.
This year’s Innovation Maturation Fund awards range from $20,000 to $35,000 and were granted to:
Brian Booth, assistant professor in the department of bioengineering, and Jeffery Edenfield, medical director at the Prisma Health Institute for Translational Oncology Research (ITOR), to further develop a collagen-type medical implant that could greatly aid in breast tissue regeneration post-lumpectomy and prevent the recurrence of tumors.
Goutam Koley, professor in the department of electrical and computer engineering, and Steve Snodgrass, pediatric pulmonologist, to develop a mobile sensor system that monitors environmental triggers for respiratory health issues that are especially prevalent in patients with respiratory illnesses. The monitoring system will utilize a battery powered miniaturized sensor system with cellular data connectivity that can be carried in person to continuously monitor specific environmental parameters for an individual.
Robert Latour, McQueen-Quattlebaum Professor in the department of bioengineering, and Sudha Garimella, clinical assistant professor in the School of Health Research and medical director of the Division of Pediatric Nephrology and Hypertension at Prisma Health–Upstate, t0 continue to develop ammonia breath-test sensors that can be used by patients with chronic kidney disease (CKD) to measure the ammonia concentration in their exhaled breath. This technology would enable patients with CKD to monitor their physiologic status within the comfort of their own homes.
Managed by the Clemson University Research Foundation, the goal of the fund is to increase applied research collaborations between Clemson faculty, graduate students and Prisma Health clinicians and to promote ideation and design of medical technology innovations that are attractive for commercialization.
“The Innovation Maturation Fund is a special funding program that was developed in conjunction with the Clemson Division of Research and Prisma Health to target unmet needs in the health care industry,” said Chris Gesswein, executive director of the Clemson University Research Foundation. “I am excited to be able to participate in granting the first round of funds to deserving researchers through this new program. An important step towards fostering and supporting innovation in health sciences, with this program we have the unique opportunity to accelerate the commercialization of medical technologies in an effort to create a more self-sustaining model for promoting growth in health care.”
“Prisma Health is excited to partner with Clemson University to engage companies and researchers in developing the next innovative breakthroughs in healthcare,” said Cody Reynolds, technology transfer manager in the Office of Innovation at Prisma Health-Upstate. “The Innovation Maturation Fund provides early-stage technical solutions to clinical opportunities and access to clinical learning environments that will equip researchers with the tools necessary to successfully obtain public and private funding.”
Arthrex has completed construction on their new South Carolina manufacturing facility see more
Brasfield & Gorrie recently completed construction on a new manufacturing facility in Anderson for Arthrex, a global orthopedic medical device company headquartered in Naples, Florida.
The $36.1 million project includes a 250,000 square foot medical device manufacturing building and a 30,000 square foot central services building. The manufacturing building consists of 175,000 square feet of manufacturing floor space and 20,000 square feet of clean room assembly space for sterile packaging activities for all manufactured medical devices. The remainder of the building is a two-story office space for support staff. Click here for the full story.
South Carolina Life Sciences Conference to Feature J&J Innovation Leader Michal Preminger, Over 40 National SpeakersSCBIO 2019 Conference Draws Speakers, Takes Center Stage October 29-31 see more
Conference registrations soar with sell-out expected; CEOs and top industry leaders from 30 states and countries expected in Greenville for strategic partnership development, industry insights
SOUTH CAROLINA – September 11, 2019 – Johnson & Johnson Innovation Leader Michal Preminger will join more than 40 additional national speakers at SCBIO 2019 – the annual conference bringing top leaders and executives from life sciences organizations across the state and nation to South Carolina October 29-31.
Following an October 29 welcome reception showcasing downtown Greenville, Ms. Preminger will address an expected sold-out conference at the Hyatt Regency with a keynote presentation entitled “Innovation for a Better Tomorrow” as the main program gets underway the morning of October 30. Her presentation will be followed by a high-powered panel comprised of regional healthcare executives entitled “Optimizing the Future of Healthcare in SC and Beyond.”
Among other featured Conference programs are EY’s “NextWave Wellness: An Interactive View of the Future of Our Industry”, and an address by South Carolina Lieutenant Governor Pamela Evette entitled “South Carolina: Just Right for Life Sciences.” Clemson University President Jim Clements headlines Day 2 with an address entitled “The Power of Partnerships in Fueling Life Sciences”, while Medtronic global executive Christian Howell will address “Driving Value-Based Care Through Collaboration".
Scores of top industry chief executives, leaders in government and higher education, biotechnology and pharma executives, clinicians and researchers, and industry supporters from across America have already registered to attend SCBIO 2019, with registration nearly doubling the record-setting pace of 2018. Other committed speakers and panelists include IQVIA Institute of Health Data Science SVP Murray Aitken, Innova Therapeutics CEO and Founder Robert Ryan, ChartSpan CEO & Founder Jon-MIchial Carter, Firststring Research President Dr. Gautam Ghatnekar, Nephron Pharmaceuticals CEO Lou Kennedy, USC President (Ret.) Harris Pastides, PhRMA Senior Regional Director Thomas Hardaway and numerous others. More than 20 programs will be featured over two days.
Themed “Ignite The Future!”, the 2+ day conference draws attendees from across America for networking, innovation updates, opportunity discovery, partnership making and strategic discussion. Committed attendees include officials across a broad spectrum of life sciences industries including medical devices, bio manufacturing, drug discovery, pharmaceuticals, diagnostics and testing, digital health and health IT, bio-ag and more. Space is limited and advance registration is still available at https://www.scbio.org/cpages/register-now-for-scbio-2019.
SCBIO is South Carolina’s investor-driven economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state. The industry has a $12 billion economic impact in the Palmetto State, with more than 670 firms directly involved and over 43,000 professionals employed directly or indirectly in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotechnology products.
SCBIO 2019 kicks off Tuesday evening October 29 with a Grand Opening Reception for conference registrants, speakers and sponsors at Greenville’s ONE Center, presented by Prisma Health. Wednesday will feature a complete day of sessions beginning at breakfast and continuing through an evening reception presented by the Greenville Area Development Corp., Greenwood Partnership Alliance and City of Greenville. The conference will conclude Thursday at lunchtime.
“Life sciences is a major driver of South Carolina’s economy, and this conference’s growth is testament to the industry’s surging impact, reach and rapidly rising economic significance in our state and region,” noted SCBIO President and CEO Sam Konduros. “Already accounting for thousands of highly-skilled jobs in the Palmetto State, this sector has tremendous growth potential, and we’re excited to showcase the top companies, research universities and leaders from across our state and country at SCBIO 2019.”
Among leading biotech and med-tech industry brands participating in the conference are Nephron Pharmaceutical, BIO, Johnson & Johnson, AVX, PhRMA, Medpoint, AdvaMed, Poly-Med, VWR, Ritedose Corporation, Rhythmlink, SoftBox Systems, ZEUS, Patheon Thermo Fisher and more. All of South Carolina’s research universities – MUSC, Clemson and the University of South Carolina – are represented, as are major healthcare systems, and economic development entities including the South Carolina Department of Commerce, SCRA, the Upstate SC Alliance, the Charleston Regional Development Alliance, Central Carolina Alliance, Economic Development Partnership and SiMT.
As the official state affiliate of BIO -- the world's largest trade association representing biotechnology organizations – along with PhRMA and AdvaMed, SCBIO members include academic institutions, biotech companies, entrepreneurial organizations, service providers, thought leaders, economic development organizations and related groups whose members are leading the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products that transform how we heal, fuel and feed the world. For additional information on SCBIO, visit www.SCBIO.org.
Life sciences in South Carolina is big business -- and getting bigger by the day. Read why... see more
In this article published simultaneously in Charleston Business Magazine, Columbia Business Magazine and Greenville Business Magazine, SCBIO CEO Sam Konduros paints a picture of the diversity of the rapidly-growing life sciences industry, and why the future is exceedingly bright -- and getting brighter -- as the $11.4 billion industry soars to new heights across South Carolina.
Life sciences in South Carolina spans a diverse spectrum—from major pharmaceutical companies to globally known medical device companies.
It encompasses start-ups and early stage innovation companies and embraces prestigious research universities and acclaimed health care systems employing some of America’s finest minds. It includes research and medical labs, bioscience-related distribution, even Bio-Ag tied to the state’s historical agricultural segment. Click to read complete article...
Clemson and Arthrex are launching a program to teach students and support the med device industry see more
The surgical device industry is continuously growing and evolving. According to data from GlobalData, the orthopedics market is expected to grow to $66 billion by 2023 from $52.8 billion in 2017. In South Carolina, medical devices are an anchor of the state's fast-growing and globally respected life sciences industry, according to executives with SCBIO -- the Palmetto State's life sciences industry organization and champion.
In response to this upward trend, surgical device companies are seeking more employees with a specialized skillset, and thanks to a new partnership with Arthrex Inc., Clemson University students will be equipped to answer the call.
A global leader in minimally invasive orthopedics, Arthrex already works with Clemson on a number of research projects. Now it’s expanding its engagement with the university through a new, two-year pilot program developed with the needs of the surgical device industry in mind and a generous gift of ten $7,500 scholarships.
“Arthrex is one of the university’s valuable strategic partners, and this opportunity to work together to create programming unique to Clemson speaks volumes about what the company thinks of our talented faculty and students,” said Clemson President James P. Clements. “This partnership is another example of Clemson’s ongoing commitment to the state of South Carolina, and I am grateful to Arthrex for its generous gift, which will enable our students to work with a world-class company to develop skills that are vital to the surgical device industry.”
“Arthrex takes great pride in its commitment to education and we are pleased to help develop the next generation of highly skilled professionals like Arthrex Technology Consultants who work with orthopedic surgeons to provide trustworthy technical product support,” said Arthrex President and founder Reinhold Schmieding.
In October 2017, Arthrex announced plans for a new $40 million facility in Sandy Springs, South Carolina. Surgical devices will be manufactured in the 290,000-square-foot facility, which is scheduled to open this summer. The new location is part of Arthrex’s efforts to expand its manufacturing base into South Carolina to create new products and jobs in America.
The pilot program will span two years and comprise a series of courses, Arthrex internships and additional learning opportunities for rising third-year students majoring in bioengineering, marketing and health sciences departments.
MKT 4950 Developing and Selling Medical Devices is the first course being offered in the series and will begin in fall 2019. Taught by Ryan Mullins in the College of Business, course material provides students an introduction to the health care industry with a focus on the development and marketing of surgical device innovations. Mullins was selected to develop the course as the Provost’s Inaugural Innovation Fellow, a program created to encourage faculty on campus to support corporate engagement efforts.
“Our collaboration with Arthrex helps us create a new type of focused course,” said Mullins. “We will walk students through real case studies at Arthrex to understand how surgical devices get translated from marketable idea to surgeon or physician adoption. This helps us illustrate the challenges inherent to both the health care marketplace and marketing of new offerings, which is not taught anywhere else.”
Students who are enrolled in the course may apply for the scholarship and additional programs offered as part of the two-year series of courses. Those who would like to participate in the entire program will take Student Affairs’ Certified Student Leader Program in the spring and an internship with Arthrex in the summer. Students outside of the participating departments can also intern with Arthrex by working with their advisers and the career center.
This partnership was developed through Clemson’s Office of Corporate Partnerships and Strategic Initiatives. Additional details regarding the scholarship, internship and second-year courses will be available soon.
Learn about South Carolina Life Sciences Feb. 20! see more
Industry subject matter experts to cover what businesses need to know
about life sciences, South Carolina’s fastest-growing industry segment
GREENVILLE, SC – February 4, 2019 – SCBIO will host a full day program February 20, 2019 -- Life Sciences Boot Camp: Insights on SC’s Fastest-Growing Industry – to inform and update businesses and professionals from across the state on opportunities, trends and issues facing South Carolina’s fastest-growing industry segment.
To be held at the University of South Carolina’s Alumni Center in Columbia, the program will run from 8:30 a.m. until 4:30 p.m. and will feature a light breakfast followed by presentations from over half a dozen noted life sciences industry leaders. Confirmed presenters and their topics are:
- Tushar Chikhliker, Partner, Nexsen Pruet, “Pharma Industry Challenges Opportunities & Legal Insights”
- Kathy Phlegar, Principal, Phlegar & Associates, “Product Development and Commercialization: The Changing Landscape of Bringing MedTech Products to Market”
- Maureen Thomas, National Institute on Aging/National Institutes on Health, “Early Stage Funding: Accessing SBIR-STTR Capital”
- Erica Jackson, Partner, K&L Gates, “Navigating the FDA: An Overview of Medical Product Approvals and Enforcement Trends”
- Dave McGlashan, Life Sciences Team Architect, DPR Construction, “Optimizing Capability & Efficiency in Your Life Sciences Facility”
- Darralyn Alexander, President, Reimbursement Strategies – “How To Gain Reimbursement For My New Technology”
- Sam Konduros, President & CEO, SCBIO – “South Carolina Life Sciences 2019: A Look Forward”
SCBIO Investor Organizations receive one registration at no charge, and additional attendees from Investor organizations pay only $50 for the entire day. Individual Members of SCBIO pay only $50 for the entire program, while the general public and Non-Members can attend for just $125. To register or for more details, visit the Events page at www.SCBIO.org/.
An additional highlight of the day’s program on “Early Stage Funding: Accessing SBIR-STTR Capital” will be when presenter Maureen Thomas is joined for discussion and open Q&A by Tyler Tatum and Ron Gorman of 3PhaseSC – South Carolina’s only free resource for SBIR/STTR grant consulting. Attendees may also schedule 1-on-1 time for afternoon discussion with Ms. Thomas between 1:15 PM and 3:30 PM for more detailed conversation and guidance.
SCBIO is South Carolina’s investor-driven public/private economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state. The industry has an $11.4 billion annual economic impact in the Palmetto State, with more than 400 firms directly involved and 15,000 professionals employed in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotech and products. The state-wide nonprofit has offices in Greenville, Columbia, and Charleston, and represents companies in the advanced medicines, medical devices, equipment, diagnostics, IT, and healthcare outcome industries. Life sciences is recognized as the fastest-growing segment of South Carolina’s knowledge economy.
SCBIO is also the official state affiliate of BIO -- the world's largest trade association representing biotechnology organizations. SCBIO’s diverse membership is leading research and development of innovative healthcare, agricultural, industrial and environmental biotech and med-tech products that will make a difference across the Palmetto State, and around the world.
For additional information on SCBIO, visit www.SCBIO.org.
Moterum selected to present at prestigious medtech conference in Chicago, IL see more
Southeastern medtech company develops mobility solutions for patients suffering from strokes, neural traumas; forum convenes investors seeking leading-edge advances in health and life sciences
GREENVILLE, S.C. – July 11, 2018 – Moterum Technologies Inc., a South Carolina-based mobility and gait rehabilitation development company, has been selected to present at the prestigious Cavendish BioHealth Impact Forum July 17-18, 2018 in Chicago, Illinois. The Forum provides an environment for organizations and investors to further their strategic social impact investing, grant-giving, and philanthropy programs in support of health and life sciences advances.
Co-hosted by Cavendish Global, the Shirley Ryan AbilityLab, and MATTER, the Forum showcases presentations and panel discussions by leading research institutions, private-sector companies, nonprofit organizations, and foundations engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment. Cavendish BioHealth Impact Forums are hosted by leading institutions around the United States and take place several times each year.
Moterum Technologies is one of 10 featured organizations invited to present their solutions at the Chicago Conference. An innovative medical technology development company, Moterum’s focus is designed to help resolve mobility and gait problems for patients suffering a neural trauma, such as a stroke. Its lead product is a fully connected, smart device that teaches stroke patients how to re-learn walking in their own home.
“We are honored to be selected to present at the 2018 Chicago Forum, and value the recognition it will provide of our innovative approach to helping stroke survivors walk independently and without a limp or asymmetry,” said David Huizenga, CEO of Moterum Technologies. “Our device can be used at home and is fully connected and positioned for telehealth systems, making it a viable solution for developed and developing health systems alike. We welcome the chance to interact with many of the world’s most accomplished scientists, thought-leaders and generous philanthropic individuals and families who are all dedicated to improving the health and lives of people around the world.”
The Cavendish community consists of over 200 leading family offices, foundations and impact investors from around the world with combined assets of over $225 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish BioHealth Impact Forum provides impact investors with a curated, peer-to-peer knowledge expansion and relationship building environment, and seeks to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing. The Forum is also an opportunity for impact investors to champion and share information on projects and organizations, which they are passionate about with other impact investors from around the world.
“With the help of our expert team, Selection Committee and advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence,” said J. Michael Moffat, Chairman of Cavendish Global. “The quality and originality of Moterum Technologies’ research and scientific insights in treating gait problems of stroke survivors positions them to make a major contribution to global health by helping stroke survivors retake an independent position in society.”
For further information on Moterum Technologies, visit www.moterum.com.
About Moterum Technologies Inc.
Moterum Technologies is an innovative medical technology development company that focuses on solving mobility and gait problems for patients suffering a neural trauma, such as a stroke. Its lead product is a fully connected, smart device that teaches stroke patients to relearn how to walk in their own home.
South Carolina's life sciences industry is booming. Read on for details... see more
From pharmaceuticals and medical devices to research and laboratory testing, the state's life sciences field is booming. The Charleston and Lowcountry region is home to many established companies and start-ups making a mark on the biomedical and health industries. Read on for the full story from Charleston Business Magazine's 2018 State of the Lowcountry Report.
South Carolina life sciences gets another huge boost with BD's $150 million investment in Sumter see more
Medical technology company creating 125 new jobs
COLUMBIA, S.C. - BD (Becton, Dickinson and Company), a leading global medical technology company, today announced a $150 million investment in its existing Sumter County manufacturing facility. The company is projected to create an additional 125 new jobs over the next several years.
Employing more than 65,000 associates worldwide, BD is one of the world's largest medical technology companies and supports health care providers in more than 190 countries. BD's Sumter County facility has been in operation since 1970, manufacturing blood collection devices that are critical to the health care industry.
Located at 1575 Airport Road in Sumter, S.C., BD's Sumter facility is actively hiring for the new positions, and interested applicants should visit www.bd.com/careers for more information.
The Coordinating Council for Economic Development has approved job development credits related to this project, as well as a $600,000 Set Aside grant to assist with the costs of road work and site preparation.
"For nearly 50 years, BD's Sumter facility has consistently delivered superior quality products, vital for our customers and their patients, through a talented and engaged workforce. We would like to thank TheLINK economic development alliance, Sumter Economic Development, the City of Sumter, Sumter County and the S.C. Department of Commerce for their continued support of BD and our employees as we continue to invest in the facility. We look forward to the ongoing success of our BD Sumter manufacturing team as they continue to advance the world of health." -BD Executive Vice President of Global Operations and Chief Supply Chain Officer Jim Borzi
"After opening in our state more than 40 years ago, we're thrilled that BD continues to grow and succeed here. This announcement once again demonstrates that South Carolina is a place where medical technology companies want to do business, and we welcome this new $150 million investment." -Gov. Henry McMaster
"Not only does our state excel in advanced manufacturing, we're also increasingly a top choice for companies in the life sciences sector. BD has been a strong member of Team South Carolina for decades, and we congratulate them on their ongoing success." -Secretary of Commerce Bobby Hitt
"BD has been a leading employer in this county since opening its doors in 1970. We are grateful for their continued investment in our community and our people." -Sumter County Council Chairman James McCain
"We have long-enjoyed BD as a key component in the fabric of our industrial portfolio. This investment demonstrates their trust in our leadership, their commitment to the success of their business and their belief in our ability to regenerate the talent needed to produce the quality of goods for which BD is known." -Sumter Economic Development Chairman Greg Thompson
FIVE FAST FACTS
- BD is investing in its existing Sumter County manufacturing facility.
- $150 million investment to create 125 new jobs.
- Employing more than 65,000 associates worldwide, BD is one of the largest medical technology companies in the world and supports health care providers in more than 190 countries.
- Located at 1575 Airport Road in Sumter, S.C., BD's facility manufactures blood collection devices for the health care industry.
BD is actively hiring for the new positions, and interested applicants should visit www.bd.com/careers for more information.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help improve patient outcomes, improve the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to better diagnose disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit www.bd.com.